Bristol Myers Squibb says Phase 3 ALOFT-IPF trial shows admilparant 60 mg meets primary endpoint

• Bristol Myers Squibb reported topline Phase 3 ALOFT-IPF results for admilparant in adults with idiopathic pulmonary fibrosis.
• The lower-dose arm met the main goal, showing a meaningful benefit versus placebo; the higher dose did not reach statistical significance.
• Safety and tolerability looked favorable across doses, with low discontinuations that were similar to placebo.
• Detailed results were not yet presented; the company plans to present them at a future medical meeting.
• A separate Phase 3 study in progressive pulmonary fibrosis is fully enrolled, with topline results expected in early 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief via Business Wire (Ref. ID: 20261011397472) on October 12, 2026, and is solely responsible for the information contained therein.